Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 49.5%

Neg 0% Neu 49.5% Pos 0%

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.